Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis
- PMID: 2254893
Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis
Abstract
To analyze whether corticosteroids in low doses during limited time periods could be safely used in the treatment of patients with polymyalgia rheumatica (PMR) or temporal arteritis (TA) the records of 91 patients diagnosed between 1980 and 1987 were reviewed. The mean initial prednisolone dose was in patients with PMR 18 mg/day and the mean duration of treatment was 17 months. In patients with TA the mean initial dose was 31 mg/day and the mean duration of treatment 16 months, and in all the corticosteroid treatment was terminated within 24 months. Patients with coexisting TA and PMR demanded longer treatment compared to patients with either TA or PMR and thus 18/91 patients were treated for more than 2 years. No visual or neurological complications occurred after treatment with corticosteroids had been initiated. Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily. With few exceptions corticosteroid treatment can be terminated within 24 months.
Similar articles
-
Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.J Rheumatol. 1999 Sep;26(9):1945-52. J Rheumatol. 1999. PMID: 10493675
-
[Rheumatic polymyalgia and temporal arteritis. Case contribution and bibliographic review].Minerva Med. 1987 Mar 15;78(5):287-96. Minerva Med. 1987. PMID: 3822219 Italian.
-
[Polymyalgia rheumatica and temporal arteritis. Observations on prognosis and treatment].Bull Acad Natl Med. 1990 Feb;174(2):263-70; discussion 270-3. Bull Acad Natl Med. 1990. PMID: 2372721 French.
-
Polymyalgia rheumatica.Clin Pharm. 1993 Aug;12(8):571-80. Clin Pharm. 1993. PMID: 8222521 Review.
-
Polymyalgia rheumatica and giant cell arteritis.Am Fam Physician. 2006 Nov 1;74(9):1547-54. Am Fam Physician. 2006. PMID: 17111894 Review.
Cited by
-
Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.J Rheumatol. 2011 Jul;38(7):1471-9. doi: 10.3899/jrheum.110275. J Rheumatol. 2011. PMID: 21724719 Free PMC article.
-
Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.J Rheumatol. 2017 Jul;44(7):1044-1050. doi: 10.3899/jrheum.161516. Epub 2017 May 1. J Rheumatol. 2017. PMID: 28461641 Free PMC article.
-
The treatment of giant cell arteritis.Rev Neurol Dis. 2008 Summer;5(3):140-52. Rev Neurol Dis. 2008. PMID: 18838954 Free PMC article. Review.
-
Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.Curr Cardiol Rep. 2014 Jul;16(7):498. doi: 10.1007/s11886-014-0498-z. Curr Cardiol Rep. 2014. PMID: 24893935 Review.
-
The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study.Rheumatol Int. 2021 Mar;41(3):605-610. doi: 10.1007/s00296-020-04654-w. Epub 2020 Jul 21. Rheumatol Int. 2021. PMID: 32696323
MeSH terms
Substances
LinkOut - more resources
Medical